This pattern reflects the chronic, relapsing nature of obesity and has prompted the WHO to recommend continuous, long-term treatment lasting six months or moreeffectively positioning these medications as lifetime therapies for many patients [51]
Yadav, V., Marracci, G., Lovera, J., Woodward, W., Bogardus, K., Marquardt, W., Shinto, L., Morris, C., & Bourdette, D
(2) Nakamura A, Nakashima M, Sugao T, Kanemoto H, Fukumura Y, Shiomi H
Prescribing GLP-1s: Evidence, limits, expectations How physicians integrate GLP1s into long-term weight management GLP-1 medications are reshaping the conversation around metabolic health and weight loss but questions remain